Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
July 22, 2016 11:30 ET
|
Synta Pharmaceuticals Corp
FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH
January 05, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
November 11, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
August 20, 2015 17:16 ET
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 06, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
PROCYSBI® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter
Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments...
Raptor Pharmaceutical to Hold Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015, at 4:30 p.m. EDT
July 30, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2015 financial results on Thursday, August 6,...
Raptor Pharmaceutical Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 07, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
Reports PROCYSBI® Sales of $20.5 Million in First Quarter
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 p.m. PT
NOVATO, Calif., May 7, 2015 (GLOBE NEWSWIRE) --...
Raptor Pharmaceutical to Host Investor Day on April 30, 2015
April 23, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) will host an Investor Day on Thursday, April 30, 2015, from 8:30 a.m. to 12:00 p.m. EDT (5:30 a.m. to 9:00...
AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform
April 22, 2015 16:01 ET
|
Exicure, Inc.
SKOKIE, Ill., April 22, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...
Raptor Pharmaceutical Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
April 08, 2015 12:13 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company focused on developing and commercializing transformative treatments for people...